Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye. We have a passion for finding new approaches for protecting or improving vision. United by VISIONaerie⢠Science, deep clinical insights, and a singular focus on addressing the unmet needs in ophthalmology, we see the possibilities ahead. Join us in creating the future of eye care. Source
No articles found.
Novanta is a leading global supplier of core technology solutions that give medica...
Novanta is a leading global supplier of core te...
Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...
Oncolytics is focused on obtaining regulatory a...
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharm...
VBL Therapeutics is a publicly traded (NASDAQ: ...
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical comp...
Orchard Therapeutics is a fully integrated comm...
Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...
Celsion Corporation is a fully integrated bioph...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
Join the National Investor Network and get the latest information with your interests in mind.